As the popularity of salvia has risen over the past 16 years—its psychoactive properties were discovered in 1993 by Daniel Siebert, an independent ethnobotanist based in Malibu, Calif.—calls to treat the plant as an illegal drug have grown louder. Twelve states have recently placed S. divinorum in their most restrictive controlled substance category, and four others have laws restricting sales. The U.S. Drug Enforcement Administration has listed salvia as “a drug of concern” and is looking into the drug to determine whether it should be declared a Schedule I controlled substance, on par with heroin and LSD.
The unusual properties of salvinorin A intrigue scientists. Psychiatric researcher Bruce Cohen and his colleagues at Harvard Medical School have been developing analogues of salvinorin A and studying their possible mood-modulating properties. The team’s work with salvinorin A in animals suggests “that a drug that would block kappa opioid receptors might be an antidepressant drug—probably a nonaddictive one—or a mood stabilizer for patients with bipolar disorder,” Cohen remarks. By activating the kappa opioid receptors, drugs such as salvinorin A could reduce dependence on stimulants and the mood-elevating and mood-rewarding effects of cocaine. Because salvinorin A can produce distortions of thinking and perception, researchers speculate that blocking the receptors might alleviate some symptoms of psychoses and dissociative disorders.
Some investigators, including the team at Harvard, believe that modified forms of salvinorin A could bolster its medicinal value. Tom Prisinzano, a medicinal chemist at the University of Kansas, points out that some chemical transformations of salvinorin A have different pharmacological abilities—such as a longer-lasting action or an enhanced ability to bind to receptors—and no hallucinogenic properties. Modifying its novel structure, he says, “could potentially treat a number of different central nervous system disorders.”
But if salvinorin A becomes a federally scheduled drug, research on it would become “much more difficult,” predicts Rick Doblin, director of the Multidisciplinary Association for Psychedelic Studies, a nonprofit based in Santa Cruz, Calif.
Full story from Scientific American.
One commenter on the Salvia story had this to say-
What about the experience with other drugs of abuse such as, indeed, LSD? Studies WERE done on them, and they didn’t result in the production of any useful medications. What REASON is there to think this would be any different?
In response, let’s ponder this story about contemporary LSD research.